s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.

BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.

“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.